CN113318166A - Plant composition and preparation method and application thereof - Google Patents

Plant composition and preparation method and application thereof Download PDF

Info

Publication number
CN113318166A
CN113318166A CN202110736386.2A CN202110736386A CN113318166A CN 113318166 A CN113318166 A CN 113318166A CN 202110736386 A CN202110736386 A CN 202110736386A CN 113318166 A CN113318166 A CN 113318166A
Authority
CN
China
Prior art keywords
parts
skin
plant composition
phase
filtering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110736386.2A
Other languages
Chinese (zh)
Other versions
CN113318166B (en
Inventor
孟宏
曲召辉
邱显荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhiran Tiancheng Beijing Biotechnology Co ltd
Original Assignee
Zhiran Tiancheng Beijing Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhiran Tiancheng Beijing Biotechnology Co ltd filed Critical Zhiran Tiancheng Beijing Biotechnology Co ltd
Priority to CN202110736386.2A priority Critical patent/CN113318166B/en
Publication of CN113318166A publication Critical patent/CN113318166A/en
Application granted granted Critical
Publication of CN113318166B publication Critical patent/CN113318166B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538Schizonepeta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a plant composition and a preparation method and application thereof, belonging to the field of skin external preparations. The composition comprises Kochiae fructus, flos Lonicerae, herba Portulacae, herba Spirodelae, mume fructus, and herba Schizonepetae. The plant composition has the effects of improving tissue vitality, and/or improving skin tissue morphology, and/or improving skin barrier related protein content, and/or relieving.

Description

Plant composition and preparation method and application thereof
The technical field is as follows:
the invention belongs to the field of skin external preparations, and particularly relates to a plant composition, and a preparation method and application thereof.
Background art:
skin refers to the tissue that wraps the body surface outside the muscles, and is the largest organ of the human body. The total weight of the skin accounts for 5-15% of the body weight, and the total area is 1.5-2 square meters. The skin covers the whole body of the human body to protect various tissues and organs in the body from physical, mechanical, chemical and pathogenic microbial attacks. The skin has a barrier effect in two ways: on one hand, the loss of water, electrolyte and other substances in the body is prevented; on the other hand, the invasion of the outside harmful substances is prevented. The skin can keep the internal environment of the human body stable and participate in the metabolic process of the human body. Impaired skin barrier can cause various problems such as dry skin, skin aging, atopic dermatitis of pigmentation, eczema, psoriasis, ichthyosis, acne, rosacea, seborrheic dermatitis, etc. The skin barrier is closely related to the vitality and the morphology of skin tissues and the contents of loricrin and filaggrin.
With the acceleration of modern life rhythm and the continuous increase of working pressure, people have more and more skin problems, and the symptoms such as dry skin, sensitivity, pruritus, desquamation, inflammation and the like continuously trouble consumers. Therefore, it is necessary to develop a natural active ingredient derived from plants, which has the effects of improving the morphology of skin tissue, increasing tissue vitality, repairing skin barrier, etc., as a raw material for skin external preparations.
Disclosure of Invention
The plant composition and the skin external preparation containing the plant composition have the effects of improving skin tissue injury, improving skin tissue vitality, increasing skin barrier related protein content, repairing skin barrier, relieving and the like.
The invention provides a plant composition.
According to the invention, the plant composition comprises the following components in parts by weight: 1-10 parts of fructus kochiae, 2-8 parts of honeysuckle, 2-8 parts of purslane, 1-6 parts of duckweed, 1-4 parts of dark plum and 1-4 parts of schizonepeta.
According to some embodiments of the invention, the plant composition comprises the following ingredients and parts by weight thereof: 3-7 parts of fructus kochiae, 3-7 parts of honeysuckle, 2-4 parts of purslane, 2-4 parts of duckweed, 1-2 parts of dark plum and 1-2 parts of schizonepeta.
According to some embodiments of the invention, the plant composition is obtained by a preparation process comprising the following steps:
extraction: adding pure water according to the feed-liquid ratio of 1:15-1:30(m/m, based on the dry weight of the raw materials), controlling the temperature at about 100-.
Coarse filtration: filtering with 100-200 mesh filter cloth to remove residue.
Fine filtering: the aperture of the filter plate is 0.2-10 μm, and the filter plate is used for filtering the solution by a plate frame until the solution is clear.
And (3) sterilization: adding 1-5% of pentanediol and 0.5-2% of hexanediol, and sterilizing for 30-60 min.
According to some embodiments of the present invention, the pore size of the middle plate frame filter plate in the fine filtration is 0.3-0.5 μm.
According to still other embodiments of the present invention, the frame filter plate is of SCP-1120 type.
According to some embodiments of the invention, the preparation process further comprises raw material sorting and cleaning.
According to the invention, the plant composition has the effects of improving tissue vitality, improving skin tissue morphology, increasing the content of skin barrier-related protein, relieving and the like.
According to the present invention, the plant composition can be widely applied as a skin external preparation.
According to the present invention, the plant composition can be applied to skin care products for external use or pharmaceutical preparations.
In another aspect of the invention, a skin cream is provided.
According to some embodiments of the present invention, the skin cream comprises the following components in parts by weight:
Figure BDA0003140223090000011
Figure BDA0003140223090000021
the skin cream of the present invention can be prepared by a conventional method in the art.
According to some embodiments of the present invention, the skin cream may be prepared by a preparation method comprising the steps of:
(1) uniformly mixing the phase A in turn, and heating until the phase A is dissolved;
(2) mixing phase B uniformly and heating until dissolving;
(3) adding phase A into phase B, stirring, homogenizing for 3-5min, adding phase C, and discharging.
The skin care cream is suitable for adults and infants.
The invention has the beneficial effects that:
the plant raw materials of fructus kochiae, honeysuckle, purslane, duckweed, dark plum and herba schizonepetae are carefully mixed to prepare the plant composition, and experiments prove that the plant composition has remarkable effects of improving tissue vitality, skin tissue morphology and skin barrier related protein content, relieving and the like, and has good application prospects in the fields of skin external preparations and the like.
Drawings
FIG. 1 is a graph of the trend of tissue viability;
FIG. 2 is a graph of tissue morphology change;
FIG. 3 is a histogram of FLG Integrated Optical Density (IOD) values;
FIG. 4 is a graph showing changes in the content of FLG protein;
FIG. 5 is a histogram of LOR Integrated Optical Density (IOD) values:
FIG. 6 is a graph showing changes in LOR protein content;
FIG. 7 is a feedback diagram of the volunteer sampling sample 1;
FIG. 8 is a feedback diagram of the volunteer sampling sample 1;
FIG. 9 is a feedback diagram of the volunteer sampling sample 1;
FIG. 10 is a feedback diagram of the volunteer sampling sample 2;
FIG. 11 is a feedback diagram of the volunteer sampling sample 3;
FIG. 12 is a feedback diagram of the volunteer sampling sample 4;
fig. 13 is a feedback diagram of the volunteer sampling sample 5.
Detailed Description
The invention is further illustrated below with reference to specific examples, to which, however, the invention is not restricted.
The experimental methods described in the following examples are all conventional methods unless otherwise specified; the experimental materials and reagents are commercially available, unless otherwise specified.
In the following examples, the starting materials used: broom cypress fruit, purslane, honeysuckle and dark plum are purchased from Beijing Qiancao Chinese herbal pieces Limited, and duckweed and herba schizonepetae are purchased from Tongrentang group.
EXAMPLES preparation of the plant compositions of the invention
Example 1: weighing 4 parts of broom cypress fruit, 4 parts of honeysuckle, 3 parts of purslane, 1.6 parts of duckweed, 1 part of dark plum and 1 part of schizonepeta; 292 parts of pure water are added according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 2: weighing 5 parts of fructus kochiae, 5 parts of honeysuckle, 3 parts of purslane, 3 parts of duckweed, 1 part of dark plum and 1 part of herba schizonepetae; 540 parts of pure water is added according to the feed-liquid ratio of 1:30 (m/m); extracting at 110 deg.C under 0.15MPa for 3 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 3: weighing 7 parts of fructus kochiae, 7 parts of honeysuckle, 4 parts of purslane, 4 parts of duckweed, 1 part of dark plum and 1 part of herba schizonepetae; 480 parts of pure water are added according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 4: weighing 1 part of fructus kochiae, 2 parts of honeysuckle, 2 parts of purslane, 1 part of duckweed, 1 part of dark plum and 1 part of herba schizonepetae; 160 g of pure water is added according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 5: weighing 4 parts of broom cypress fruit, 4 parts of honeysuckle, 3 parts of purslane, 1.6 parts of duckweed, 1 part of dark plum and 1 part of schizonepeta; 292 parts of pure water are added according to the feed-liquid ratio of 1:20 (m/m); extracting at 100 deg.C under 0.1MPa for 1 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 6: weighing 4 parts of broom cypress fruit, 4 parts of honeysuckle, 3 parts of purslane, 1.6 parts of duckweed, 1 part of dark plum and 1 part of schizonepeta; 292 parts of pure water are added according to the feed-liquid ratio of 1:20 (m/m); extracting at 130 deg.C under 0.3MPa for 3 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 7: weighing 5 parts of fructus kochiae, 5 parts of honeysuckle, 2 parts of purslane, 1 part of duckweed, 3 parts of dark plum and 3 parts of herba schizonepetae; 380 parts of pure water is added according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 1 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 8: weighing 1 part of fructus kochiae, 2 parts of honeysuckle, 2 parts of purslane, 6 parts of duckweed, 4 parts of dark plum and 4 parts of herba schizonepetae; adding 285 parts of pure water according to the feed-liquid ratio of 1:15 (m/m); extracting at 110 deg.C under 0.15MPa for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Example 9: weighing 10 parts of fructus kochiae, 8 parts of honeysuckle, 8 parts of purslane, 6 parts of duckweed, 4 parts of dark plum and 4 parts of herba schizonepetae; adding 800 parts of pure water according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Comparative example
Comparative example 1: weighing 4 parts of broom cypress fruit, 4 parts of honeysuckle, 3 parts of purslane, 1.6 parts of duckweed, 1 part of dark plum and 1 part of schizonepeta; 292 parts of pure water are added according to the feed-liquid ratio of 1:20 (m/m); extracting at 80 deg.C under normal pressure for 2 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Comparative example 2: weighing 1 part of fructus kochiae, 2 parts of honeysuckle, 1 part of purslane, 7 parts of duckweed, 7 parts of dark plum and 7 parts of herba schizonepetae; adding 500 parts of pure water according to the feed-liquid ratio of 1:20 (m/m); extracting at 110 deg.C under 0.15MPa for 1 hr; filtering the extractive solution with 200 mesh filter cloth, and filtering with 0.3-0.5 μm filter plate; adding 2% pentanediol and 1.5% hexanediol for antisepsis, and sterilizing in water bath at 90-95 deg.C for 30min to obtain extract.
Evaluation of advantageous effects
The 3D skin model is an active tissue which is similar to a human skin structure and is formed by reconstructing normal human skin cells separated in vitro by using a fine-adjustment serum-free culture medium by using a tissue engineering technology. The 3D epidermal model is a 3D epidermal model which takes keratinocytes separated from Chinese skin tissues as seed cells and promotes the cells to develop into a multi-layered structure in vitro by using a fine-adjusted serum-free culture medium. The 3D epidermal model is highly similar in histological structure to human skin structure, and contains stratum corneum (stratum corneum), stratum granulosum (stratum granulosum), stratum spinosum (stratum spinosum), and stratum basale (stratum basale). The 3D epidermis model has a laminated structure, physiological and metabolic functions which are highly similar to those of natural skin, and can be widely used for detection in the fields of in-vitro corrosion, stimulation, barrier repair and the like.
The specific experimental method is as follows:
1. test solution configuration
(1) MTT working solution preparation
MTT stock solutions at 5mg/mL were prepared in PBS and stored at-20 deg.C (storage time not longer than 1 month). Before use, the stock solution was diluted to 1mg/mL with PBS solution and kept at 4 ℃ in the dark (the stand-by time is not more than 2 h).
(2) Preparation of Induction working solution
C and LPS induced working solution: dissolving 480 mu L of 5mg/mL PolyI: C mother liquor and 20 mu L of 10mg/mL LPS mother liquor in 100mL skin model culture solution to ensure that the final concentration of the PolyI: C is 24 mu g/mL; the final concentration of LPS was 20. mu.g/mL.
(3) Positive control group (50. mu.M WY14643) working solution preparation
Weighing 10mg of WY14643 powder, dissolving in 1mL of DMSO, and preparing 30mM WY14643 mother liquor; mu.L of WY14643 stock solution (30mM) was added to 6mL of the model culture solution to prepare 50. mu.M of a working solution for use.
2. Administration and Induction procedures
(1) And (4) leaving the model out of the factory: the skin model was transferred to a 6-well plate (small molds were added in advance and 3.7mL of skin model culture solution was added), and the 6-well plate was marked with the test group number.
(2) Administration: adding 25 μ L of sample to be measured on the surface of the model, uniformly coating, and placing in CO2Incubator (37 ℃, 5% CO)2) And (4) performing medium incubation for 24 h.
(3) Induction: after the dosing incubation was completed, the 6-well plate was removed from the incubator. The surface of the model was lightly wiped with a sterile cotton swab. And (4) sucking and removing residual culture solution in the holes, adding PolyI: C and LPS induction working solution into the negative control group, the positive control group and the sample group, and adding model culture solution into the blank control group. Transfer all 6 well plates to CO at end2Incubator (37 ℃, 5% CO)2) And (4) performing medium incubation for 24 h.
3. Tissue viability assay
The experimental method comprises the following steps:
MTT incubation: the washed model was placed in a 24-well plate containing 1mg/mL MTT working solution. Subsequent transfer of 24-well plates to CO2Incubator (37 ℃, 5% CO)2) Incubate for 3 h.
2. And (3) isopropanol leaching: after the completion of the MTT incubation, the mold was removed with tweezers, the MTT liquid remaining on the bottom surface was wiped with absorbent paper, transferred to a new 24-well plate, 2mL of isopropyl alcohol was added, the 24-well plate was sealed with a sealing film, and allowed to stand overnight at 4 ℃.
3. And (3) detection: after the leaching was completed, the mold was pierced with a 200 μ L pipette tip, and the isopropanol leaching solution was allowed to flow out of the mold into a 24-well plate. The pierced mold was discarded and the isopropanol extract from each well was whipped 3 times and mixed well. After mixing, 2 parts of 200. mu.L isopropanol leaching solution is absorbed from each well, and added into corresponding wells of a 96-well plate respectively for marking. The absorbance value is read by a microplate reader at the wavelength of 570 nm.
The experimental results are as follows:
as shown in fig. 1, compared to the BC group (blank control group), the tissue viability of the NC group (negative control group) was significantly decreased, indicating that the stimulation conditions were effective in this experiment. Compared with the NC group, the tissue viability of the PC (WY14643) group (positive control) was significantly increased, indicating that this positive control assay was effective. Compared with the NC group, the tissue viability of the example 1 and the example 2 is obviously improved, which shows that the invention has the efficacy of improving the skin tissue viability; whereas comparative examples 1 and 2 showed no tendency to increase tissue viability.
Tissue morphology detection
The experimental method comprises the following steps:
fixing the model for tissue morphology with 4% paraformaldehyde, fixing for 24H, cutting off the model, performing H & E staining, taking a picture under a microscope, and collecting the picture.
The results of the experiment are shown in FIG. 2. The tissue morphology detection result shows that compared with the BC group, the NC group model has the advantages of reduced number of basal layer cells, disordered arrangement, unclear boundaries of four-layer structures, vacuoles (yellow arrows) and appearance of damaged cells (yellow circles), and the experiment shows that the stimulation condition is effective. Compared with the NC group, the damage condition of the PC (WY14643) group model is obviously improved, which shows that the positive control detection is effective. Compared with NC group, the administration group model of example 1 and example 2 has obviously reduced vacuole and damaged cells and improved damaged condition, which shows that the invention has the efficacy of improving the skin tissue morphology.
Skin barrier associated protein content assay
Filaggrin (FLG) is an important component of the horny layer, is synthesized by horny substance-forming cells, is distributed in different parts of the horny layer, is gradually degraded by enzyme along with the process of the horny substance-forming cell migration, is degraded into small molecular substances required by the horny layer of a natural moisturizing factor, and plays an important role in the aspects of moisturizing and barrier integrity.
Loricrin (LOR) is a major component of the cornified envelope and plays an important role in the barrier function of the epidermis.
The experimental method comprises the following steps:
1. baking sheets and dewaxing: the paraffin sections were placed in a 70 ℃ baking machine and baked for 4 hours.
2. Dewaxing and hydrating: soaking the slices in xylene for 10min, replacing xylene, soaking for 10min, soaking in anhydrous ethanol for 5min, soaking in 95% ethanol for 5min, and soaking in 75% ethanol for 5 min. The cells were washed 3 times with PBS buffer for 5min each time.
3. Antigen retrieval: and (3) putting the paraffin sections into 0.01M sodium citrate antigen retrieval solution, performing high-pressure retrieval, cooling and taking out the sections. The washing was performed 3 times for 5 min/time with PBS buffer.
4. Blocking peroxidase: 1 drop of 3% H2O2 was added to each section and incubated at room temperature for 30min to block endogenous peroxidase activity. The washing was performed 3 times for 5 min/time with PBS buffer.
5. Serum blocking: and (4) dropwise adding serum homologous with the secondary antibody, sealing for 60min at 37 ℃, and washing is not needed.
6. Primary antibody incubation: add the primary antibody solution dropwise and incubate overnight at 4 ℃. The washing was performed 3 times for 5 min/time with PBS buffer.
7. And (3) secondary antibody incubation: and adding a secondary antibody working solution dropwise, and incubating for 1h at room temperature. The washing was performed 3 times for 5 min/time with PBS buffer.
ABC complex incubation: dripping ABC compound solution, and incubating for 30min at room temperature. The washing was performed 3 times for 5 min/time with PBS buffer.
And 9, DAB dyeing: and adding 1 drop of freshly prepared DAB solution (the specific part can be dyed brown) into each section, and observing for 5-30 s by using a microscope.
10. Counterdyeing: hematoxylin counterstain for 30 s.
11. And (3) dehydrating: dehydrating the slices with gradient alcohol (75%, 95%, 100%, 100%) for 5min, soaking in xylene for 10min, replacing xylene, soaking for 10min, drying, sealing with neutral resin, sun drying, and observing.
FLG experimental results:
the FLG Integrated Optical Density (IOD) values are summarized in FIG. 3:
compared with the BC group, the content of the FLG protein in the NC group is obviously reduced, which shows that the experimental stimulation condition is effective. Compared with the NC group, the content of the FLG protein in the PC (WY14643) group is obviously increased, which indicates that the positive control detection is effective. Compared with the NC group, the content of the FLG protein in the examples 1 and 2 is obviously increased, which shows that the invention has the efficacy of improving the skin barrier related protein FLG.
The image taken under the microscope is shown in fig. 4.
LOR test results:
the LOR Integrated Optical Density (IOD) values are summarized in fig. 5:
compared with the BC group, the LOR protein content of the NC group is obviously reduced, which shows that the experimental stimulation condition is effective. Compared with the NC group, the LOR protein content of the PC (WY14643) group is obviously increased, which indicates that the positive control detection is effective. The FLG protein content of example 1 and example 2 was significantly increased compared to the NC group, indicating that the present invention has efficacy of increasing LOR of skin barrier-associated protein.
The image taken under the microscope is shown in fig. 6.
Trial experiment of population
After the extract is prepared into cream according to the following formula, the trial evaluation of people with related barrier and tissue problems on skin is carried out, the effect is obvious, and the tissue damage is improved.
TABLE 1 cream watch
Figure BDA0003140223090000061
The preparation process steps for samples 1-3 are as follows:
(1) uniformly mixing the phase A in turn, and heating until the phase A is dissolved;
(2) mixing phase B uniformly and heating until dissolving;
(3) adding phase A into phase B, stirring, homogenizing for 3min, adding phase C, and discharging.
The preparation process steps of samples 3-5 are as follows:
(1) uniformly mixing the phase A in turn, and heating until the phase A is dissolved;
(2) mixing phase B uniformly and heating until dissolving;
(3) adding phase A into phase B, stirring, homogenizing for 5min, adding phase C, and discharging.
The specific test method for the trial of the population is as follows:
the age of the recruited volunteers is 2-60 years, the characters are unlimited, the skin has the problems of dry itch, desquamation, redness, tissue epidermis damage and the like, the total number of the recruited volunteers is 50, the recruited volunteers are randomly divided into 5 groups, and 10 patients in each group are used for sampling. Group 1 using sample 1, group 2 using sample 2, group 3 using sample 3, group 4 using sample 4, group 5 using sample 5.
The sample is smeared on the skin at the improper position every morning and evening, and is massaged until the sample is absorbed, and the smearing times can be increased according to the self condition.
The results of the trial population are shown in figures 7-13.
10 volunteers in group 1 all fed back that sample 1 had an immediate antipruritic effect; 4 volunteers fed back the desquamation state of the skin for 1 day to improve; the skin tissue morphology can be seen to be gradually restored by feeding back 2 volunteers for more than 3 days, and the skin tissue morphology is restored by feeding back 2 volunteers for 15 days.
10 volunteers in group 2 all fed back that sample 2 had an immediate antipruritic effect; the volunteer does not feed back the improvement of the desquamation state of the skin; the wound of the skin lesion was converged after the 2 volunteers fed back for 3 days, and recovered after the 3 volunteers fed back for 25 days.
10 volunteers in 3 groups all fed back that sample 3 had an immediate antipruritic effect; the skin desquamation state of 3 volunteers is improved after being fed back for 1 day, the skin tissue morphology is completely recovered after 1 volunteer is fed back for 5 days, and the skin tissue morphology is recovered after 3 volunteers are fed back for 15 days.
7 feedback samples 4 of 10 volunteers in 4 groups had immediate antipruritic effect; 3 volunteers fed back that the skin desquamation status improved for 1 day, and 2 volunteers fed back that the skin tissue morphology began to improve after 7 days of use.
3 feedback samples 5 of 10 volunteers in 5 groups had immediate antipruritic effect; 2 volunteers fed back the desquamation state of skin for 2 days; no volunteers fed back the improvement of the skin tissue morphology.
From the feedback of volunteers, samples 1-3 have excellent instant itching relieving effect, samples 4-5 have poor instant itching relieving effect, and especially sample 5, only 3 volunteers feedback sample 5 has instant itching relieving effect; both the sample 1 and the samples 3-4 have better effect of relieving the symptoms of the skin desquamation, only 2 volunteers feed back the sample 5 to have the effect of relieving the symptoms of the skin desquamation, and no volunteer feeds back the sample 2 to have the effect of relieving the symptoms of the skin desquamation; samples 1-4 had good effects of repairing skin tissue conditions, and no volunteer feedback sample 5 had effects of repairing skin tissue conditions.
The trial pictures of some volunteers are shown in fig. 7-13, and fig. 7-9 are the trial feedback pictures of sample 1. FIG. 7 shows that the elbow parts of the volunteers had desquamation and redness, and the elbow state was completely restored 5 days after the application of the sample 1. FIG. 8 the arm of the volunteer had a red swelling phenomenon, which subsided after 1 week with the sample and recovered substantially. FIG. 9 shows that the lower leg of the volunteer showed a large-area red-going phenomenon, which started to improve 5 days after using the sample 1 and was almost completely recovered 15 days after using the sample.
Fig. 10 is a feedback picture of the volunteer who tried sample 2, and the wound of the hand back skin injury starts to converge and gradually improves 3 days after the volunteer uses the feedback picture.
Fig. 11 is a feedback picture of the volunteer who tried the sample 3, and the sole is completely recovered after being used for 10 days at the molting and damaged part.
Fig. 12 is a feedback picture of the volunteer who tried the sample 4, the feedback picture has an instant itching relieving effect after smearing, and the finger breakage symptom is slightly relieved after 10 days of use.
FIG. 13 is a feedback picture of the volunteer who tried sample 5 and had a large area of broken ankle skin, and the symptoms were not substantially reduced after using the sample for 10 days.
From the view of onset time and effect, the sample 1 has excellent effects of relieving the symptoms of desquamation and red swelling of the skin, and the phenomena of desquamation, red swelling and red swelling of the skin of a volunteer are basically and completely recovered after 7 days of use; sample 2 had a better effect of repairing the tissue state, and the skin wound started to converge after 3 days after use; sample 3 had a good effect of repairing the tissue state, and skin molt damage was substantially completely restored after 10 days of use; sample 4 had slightly reduced skin damage symptoms after 10 days of use, with a slow onset of action; the symptoms of skin breakdown were not substantially reduced after 10 days of sample 5 use.
In conclusion, the feedback and the using effect are tried out by volunteers, and the plant composition has good skin tissue repairing effect, can be used by adults and children, and is free of irritation.

Claims (10)

1. The plant composition is characterized by comprising the following raw materials in parts by weight: 1-10 parts of fructus kochiae, 2-8 parts of honeysuckle, 2-8 parts of purslane, 1-6 parts of duckweed, 1-4 parts of dark plum and 1-4 parts of schizonepeta.
2. The plant composition of claim 1, wherein the plant composition comprises the following raw materials in parts by weight: 3-7 parts of fructus kochiae, 3-7 parts of honeysuckle, 2-4 parts of purslane, 2-4 parts of duckweed, 1-2 parts of dark plum and 1-2 parts of schizonepeta.
3. The plant composition of claim 1 or 2, wherein said plant composition is obtained by a preparation process comprising the steps of:
s1: adding pure water according to the material-liquid ratio of 1:15-1:30(m/m), controlling the temperature at 100-.
4. The plant composition of claim 3, wherein the plant composition preparation process further comprises:
s2: s1, filtering the extract with 100-200 meshes of filter cloth, and filtering to remove residue to obtain primary filtrate;
s3: and (4) filtering the primary filtrate obtained in the step (S2) by using a plate frame until the feed liquid is clear, wherein the aperture of a filter plate is 0.2-10 mu m.
5. The plant composition of claim 4, wherein the plant composition preparation process further comprises:
s4: and (S3) adding 1-5% of pentanediol and 0.5-2% of hexanediol into the filtrate, and sterilizing for 30-60 min.
6. Use of the plant composition of any one of claims 1 to 5 in a skin external preparation.
7. The use according to claim 6, wherein the skin external preparation has an effect of increasing tissue viability, and/or improving skin tissue morphology, and/or increasing skin barrier-associated protein content, and/or soothing.
8.A skin care product, which is characterized by comprising the plant composition as claimed in any one of claims 1 to 5 and conventional auxiliary materials in the field of skin care products.
9. The skin-care cream is characterized by comprising the following raw materials in parts by weight:
Figure FDA0003140223080000011
10. the skin cream of claim 9, wherein the skin cream is prepared by a preparation method comprising the steps of:
(1) uniformly mixing the phase A in turn, and heating until the phase A is dissolved;
(2) mixing phase B uniformly and heating until dissolving;
(3) adding phase A into phase B, stirring, homogenizing for 3-5min, adding phase C, and discharging.
CN202110736386.2A 2021-06-30 2021-06-30 Plant composition and preparation method and application thereof Active CN113318166B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110736386.2A CN113318166B (en) 2021-06-30 2021-06-30 Plant composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110736386.2A CN113318166B (en) 2021-06-30 2021-06-30 Plant composition and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113318166A true CN113318166A (en) 2021-08-31
CN113318166B CN113318166B (en) 2022-10-28

Family

ID=77423519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110736386.2A Active CN113318166B (en) 2021-06-30 2021-06-30 Plant composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113318166B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199510A1 (en) * 2021-03-23 2022-09-29 太和康美(北京)中医研究院有限公司 Alleviating and repairing composition, and preparation method therefor and use thereof
WO2022252761A1 (en) * 2021-05-31 2022-12-08 植然天成(北京)生物科技有限公司 Soothing repair cream and preparation method therefor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569675A (en) * 2009-05-26 2009-11-04 李彩萍 Chinese medicament for treating tinea of feet and hands and preparation method thereof
CN105560331A (en) * 2015-12-30 2016-05-11 西安医学院 Eczematous dermatitis prevention medicine, and preparation method and application thereof
CN108066216A (en) * 2017-12-27 2018-05-25 国东启 A kind of antiallergic releive composition, include its cleanser and preparation method
CN108403764A (en) * 2018-06-01 2018-08-17 四川省中医药科学院 A kind of external preparation and preparation method for treating Facial Recurrent Dermatitis
CN109846770A (en) * 2018-01-05 2019-06-07 上海珈凯生物科技有限公司 It is a kind of to have effects that slow down plant extract composition of skin irritatin and preparation method thereof, application
CN110940813A (en) * 2019-10-31 2020-03-31 广州市华代生物科技有限公司 In-vitro method for evaluating repair function by adopting reconstructed normal human body three-dimensional skin model
CN112263522A (en) * 2020-11-05 2021-01-26 广州市中通生化制品有限公司 Composition for relieving and repairing skin and application thereof
CN113181089A (en) * 2021-03-23 2021-07-30 太和康美(北京)中医研究院有限公司 Soothing and repairing composition and preparation method and application thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569675A (en) * 2009-05-26 2009-11-04 李彩萍 Chinese medicament for treating tinea of feet and hands and preparation method thereof
CN105560331A (en) * 2015-12-30 2016-05-11 西安医学院 Eczematous dermatitis prevention medicine, and preparation method and application thereof
CN108066216A (en) * 2017-12-27 2018-05-25 国东启 A kind of antiallergic releive composition, include its cleanser and preparation method
CN109846770A (en) * 2018-01-05 2019-06-07 上海珈凯生物科技有限公司 It is a kind of to have effects that slow down plant extract composition of skin irritatin and preparation method thereof, application
CN108403764A (en) * 2018-06-01 2018-08-17 四川省中医药科学院 A kind of external preparation and preparation method for treating Facial Recurrent Dermatitis
CN110940813A (en) * 2019-10-31 2020-03-31 广州市华代生物科技有限公司 In-vitro method for evaluating repair function by adopting reconstructed normal human body three-dimensional skin model
CN112263522A (en) * 2020-11-05 2021-01-26 广州市中通生化制品有限公司 Composition for relieving and repairing skin and application thereof
CN113181089A (en) * 2021-03-23 2021-07-30 太和康美(北京)中医研究院有限公司 Soothing and repairing composition and preparation method and application thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
张喜军,等: "马齿苋在皮肤病中的临床应用", 《中国社区医师》 *
施慧,著: "《常见皮肤病图谱与中医效验方》", 31 January 2018, 中国医药科技出版社 *
李建广,等: "中药药浴治疗皮炎湿疹类皮肤病疗效观察", 《中国实验方剂学杂志》 *
杨贤平,等: "中药对皮肤屏障功能修复作用的研究进展", 《吉林中医药》 *
王雪梅,编著: "《画眉深浅入时无:化妆品与健康美容》", 30 September 2004, 安徽大学出版社 *
胡一梅,等: "马齿苋提取液对急性湿疹大鼠皮肤屏障功能的调控作用", 《重庆医学》 *
胡一梅,等: "马齿苋提取物对接触性皮炎大鼠皮肤丝聚蛋白和半胱氨酸天冬氨酸特异性蛋白酶-14蛋白表达的影响", 《临床皮肤科杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199510A1 (en) * 2021-03-23 2022-09-29 太和康美(北京)中医研究院有限公司 Alleviating and repairing composition, and preparation method therefor and use thereof
WO2022252761A1 (en) * 2021-05-31 2022-12-08 植然天成(北京)生物科技有限公司 Soothing repair cream and preparation method therefor

Also Published As

Publication number Publication date
CN113318166B (en) 2022-10-28

Similar Documents

Publication Publication Date Title
CN113318166B (en) Plant composition and preparation method and application thereof
KR101208012B1 (en) Cosmetic composition containing snail mucus fed with red ginseng and producing method thereof
KR101724147B1 (en) Cosmetic composition having anti-itching effect containing crude drug extracts
CN106420459B (en) A kind of ginseng water Essence living and preparation method thereof and the facial mask comprising it
KR101098400B1 (en) A method for mucus of acusta despecta sieboldiana feed red ginseng and cosmetic composition containing thereof
KR102047214B1 (en) Composition for scalp care and manufacturing method thereof
CN110960457A (en) Preparation method of apocynum venetum extract and application of apocynum venetum extract in whitening and skin-care products
CN109135974B (en) Bee venom beauty handmade soap and preparation method thereof
EP3689330A1 (en) Cosmetic and pharmaceutical compositions each containing aloe extract and upland rice extract
EP2589603A1 (en) Vegf production promoter
CN113143835B (en) Plant combined enzyme for removing mites and acnes as well as preparation method and application thereof
WO2021082889A1 (en) Environmentally-friendly method of preparing composition containing anti-inflammatory active ingredient and application thereof
TW382593B (en) Hypoglycemic agents from harungana or vismia spp.
CN109077985B (en) Skin care composition and application thereof
CN114652763A (en) Plant fermentation allergy-relieving composition and preparation method and application thereof
CN111939097A (en) Moisturizing and allergy-relieving composition and application thereof
CN110772473B (en) Skin care product suitable for skin of diabetic patient
CN115670980B (en) Compound essential oil with skin protection effect and skin care product composition containing compound essential oil
KR20140131027A (en) Skin external composition containing ginsenoside Rh4
CN114948932B (en) Use of a composition comprising mulberenone for the preparation of a product for the prevention and treatment of hair loss by acting on the hair follicle tissue
CN116422002B (en) Aloe extract and preparation method and application thereof
CN106389673A (en) Traditional Chinese medicine composition extract with effect of acne removal and whitening and application thereof
KR102610940B1 (en) Preparing method of cosmetic composition using skin cosmetic solution
KR20240075227A (en) A COSMETIC COMPOSITION FOR PREVENTING, IMPROVING OR TREATING ATOPIC DERMATITIS CONTAINING FERMENTED PRODUCT OF Amelanchier asiatica AS AN ACTIVE INGREDIENT AND ITS MANUFACTURING METHOD
Rahmadianti et al. Antioxidant Gel from Brown Algae (Ascophyllum nodosum) and Binahong Leaves for Diabetic Wound Healing

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 101200 Building 2, yard 62, Pingwang street, Zhongguancun Science and Technology Park, Pinggu District, Beijing

Applicant after: Zhiran Tiancheng (Beijing) Biotechnology Co.,Ltd.

Address before: 101200 Building 2, plot f05-02, Pingwang street, Xinggu district a, Zhongguancun Science and Technology Park, Pinggu District, Beijing

Applicant before: Zhiran Tiancheng (Beijing) Biotechnology Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant